Clinical trial
A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Design Trial to Evaluate the Safety and Efficacy of Denifanstat in Participants With Moderate to Severe Acne Vulgaris
NCT07863193 is registered in ClinicalTrials.gov with Sagimet Biosciences Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Design Trial to Evaluate the Safety and Efficacy of Denifanstat in Participants With Moderate to Severe Acne Vulgaris
- Lead sponsor
- Sagimet Biosciences Inc.
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- October 31, 2026
- Completion date
- April 30, 2028
- Enrollment
- 800 (estimated)
- Sites
- 4
Conditions
As the registry lists them; a condition with its own page is linked.